| FMO1 substrate |
| Itopride |
| Itopride (INN) |
| Itopride hydrochloride (JAN) <JP> |
| Teneligliptin |
| Teneligliptin (INN) |
| Teneligliptin hydrobromide hydrate (JAN) <JP> |
| Teneligliptin hydrobromide (JAN) |
| Risdiplam (JAN/USAN/INN) <JP/US> |
| Teneligliptin and canagliflozin <JP> |
| FMO3 substrate |
| Itopride |
| Itopride (INN) |
| Itopride hydrochloride (JAN) <JP> |
| Teneligliptin |
| Teneligliptin (INN) |
| Teneligliptin hydrobromide hydrate (JAN) <JP> |
| Teneligliptin hydrobromide (JAN) |
| Dasatinib |
| Dasatinib (JAN/INN) <JP> |
| Dasatinib (USAN); Dasatinib hydrate (JAN) <JP/US> |
| Dasatinib laurylsulfate (USAN) |
| Fedratinib |
| Fedratinib (USAN/INN) |
| Fedratinib hydrochloride (USAN); Fedratinib hydrochloride hydrate (JAN) <US> |
| Risdiplam (JAN/USAN/INN) <JP/US> |
| Almotriptan |
| Almotriptan (USAN) |
| Almotriptan malate (USP) <US> |
| Teneligliptin and canagliflozin <JP> |
| Neratinib |
| Neratinib (USAN/INN) |
| Neratinib maleate <US> |
